Fucoidans in Nanomedicine

Chollet, Lucas; Saboural, Pierre; Chauvierre, Cédric; Villemin, Jean-Noël; Letourneur, Didier; Chaubet, Frédéric

doi:10.3390/md14080145

Cited by 94 publications

(57 citation statements)

References 200 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been previously demonstrated in vivo by us and other groups, that fucoidan-functionalized nanoparticles or microparticles targeting P-selectin can be used for the diagnosis of endothelial activation and intraluminal thrombosis, and for tumor-selective drug delivery [29][30][31]. Fucoidan refers to a type of highly sulfated polysaccharide containing L-fucose groups [32]. This natural compound exhibits a high affinity for P-selectin, mimicking its main ligand the P-selectin Glycoprotein Ligand 1 (PSGL-1) [33].…”

Section: Introductionmentioning

confidence: 99%

Thrombolytic therapy based on fucoidan-functionalized polymer nanoparticles targeting P-selectin

et al. 2018

Self Cite

View full text Add to dashboard Cite

Injection of recombinant tissue plasminogen activator (rt-PA) is the standard drug treatment for thrombolysis. However, rt-PA shows risk of hemorrhages and limited efficiency even at high doses. Polysaccharide-poly(isobutylcyanoacrylate) nanoparticles functionalized with fucoidan and loaded with rt-PA were designed to accumulate on the thrombus. Fucoidan has a nanomolar affinity for the P-selectin expressed by activated platelets in the thrombus. Solid spherical fluorescent nanoparticles with a hydrodynamic diameter of 136 ± 4 nm were synthesized by redox radical emulsion polymerization. The clinical rt-PA formulation was successfully loaded by adsorption on aminated nanoparticles and able to be released in vitro. We validated the in vitro fibrinolytic activity and binding under flow to both recombinant P-selectin and activated platelet aggregates. The thrombolysis efficiency was demonstrated in a mouse model of venous thrombosis by monitoring the platelet density with intravital microscopy. This study supports the hypothesis that fucoidan-nanoparticles improve the rt-PA efficiency. This work establishes the proof-of-concept of fucoidan-based carriers for targeted thrombolysis.

show abstract

Section: Introductionmentioning

confidence: 99%

Thrombolytic therapy based on fucoidan-functionalized polymer nanoparticles targeting P-selectin

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…In this work, we propose the use of nontoxic Fu to develop a natural marine-origin drug delivery system (DDS) for the release of anticancer drugs. Indeed, Fu have been included in nanosystems for diagnostic, drug delivery and regenerative medicine [9,10] and have been combined with chitosan (CH), a marine-derived polycation, to prepare…”

mentioning

confidence: 99%

Gemcitabine Delivered by Fucoidan/Chitosan Nanoparticles Presents Increased Toxicity Over Human Breast Cancer Cells

Oliveira

Neves

Reis

et al. 2018

Nanomedicine (Lond.)

View full text Add to dashboard Cite

show abstract

“…Then, the second-generation antidepressants comprise serotoninnorepinephrine reuptake inhibitors norepinephrine reuptake inhibitors, the selective serotonin reuptake inhibitors. Although there is so much of advancement in the field of medicine, there is a drawback in the treatment of depression, and there is a failure to remission of the disease [32,33]. Moreover, there are still cases like so many; adverse events have been causing for the patients from various types of the system like refractory responsiveness.…”

Section: Apoorva Et Almentioning

confidence: 99%

Medicinal Herbs and Phytochemicals Used in the Treatment of Depression: A Review

Mehdi

et al. 2019

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Depression is a condition of no mood and loss of interest in any activity that can diminish a person’s thinking, conduct, tendencies, emotional state, and a sense of well-being. Although there is a conventional class of medication which have been beneficial in the treatment of depression, current studies have reported having side effects which can be minimized by the intervention of herbs and phytochemicals. Most of the studies have proven the various mechanisms and have started to research a very ground-breaking method by glancing the ancient treatmen. Where this new approach of using the herbs and phytochemicals has shown better results alone and in combination with conventional drugs which has shown lesser adverse effects. The practice of phytomedicine is an additional option for the treatment of depression. In the various segments of treating the depression, the mainstream can be a breakthrough including phytoconstituents. In this aspect, there are many contributions for the treatment of the depression acting to the neuronal level signaling and the phytoconstituents also have shown some basic mechanisms in the treatment of depression as that of the conventional medications following some primary hypothesis and signaling pathways and life interactions that effects the brain in either way to treat the depression in all sort of way. Clinical evidence is required to provide backing to the safety and effectiveness of herbs and phytochemicals alone or in combination with currently available drugs to overcome the reported side effects during the treatment of depression.

show abstract

Fucoidans in Nanomedicine

Cited by 94 publications

References 200 publications

Thrombolytic therapy based on fucoidan-functionalized polymer nanoparticles targeting P-selectin

Thrombolytic therapy based on fucoidan-functionalized polymer nanoparticles targeting P-selectin

Gemcitabine Delivered by Fucoidan/Chitosan Nanoparticles Presents Increased Toxicity Over Human Breast Cancer Cells

Medicinal Herbs and Phytochemicals Used in the Treatment of Depression: A Review

Contact Info

Product

Resources

About